Skip to content

AbCellera Biologics Inc.

ABCL Nasdaq SEC CIK 1703057

Follow AbCellera Biologics Weekly email: filings, results, news

News

10 stories filed under AbCellera Biologics, grouped into ongoing threads

Treatment

Thread · 3 stories

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

Markets 45 d ago

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes - Slideshow

Markets 45 d ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Markets 48 d ago also on ET

More coverage

Abcellera Biologics stock hits 52-week high at 11.51 USD

Markets 38 d ago

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

Markets 40 d ago

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

Markets 41 d ago also on VRTX VERX

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Markets 43 d ago 2 sources

AbCellera Biologics stock analysis: momentum vs. fundamentals

Markets 43 d ago

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation

Earnings 49 d ago

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

Earnings 50 d ago

Next results

NOV4

FY 2026 results

Wednesday · estimated from the filing cadence

Profile

Headquarters: VANCOUVER
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 10 stories clustered from the RSS aggregator